Press Releases

June 2, 2014 - Sea Lane and Agensys announce commercial license agreement for antibodies generated using ConCIRT Libraries

June 12, 2013 - Sea Lane and Takeda announce multi-year, multi-target discovery license agreement for the use of Sea Lane’s ConCIRT libraries and technology

September 16, 2012 - Craigslist Enables Medical Breakthrough at Bay Area Biotech - Sea Lane Biotechnologies Demonstrates Cross-neutralization of Influenza A Viruses Mediated by a Single Antibody Loop

May 5, 2012 - Sea Lane Biotechnologies, LLC Successfully Generates and Delivers Therapeutic Candidates In Discovery Research Collaboration with Agensys, Inc., an Affiliate of Astellas Pharma Inc.

November 2, 2010 - Sea Lane Biotechnologies is Awarded Qualifying Therapeutic Discovery Project Grants for Six Separate Programs
Grants total $1,466,875.50 to support Surrobody™ and antibody development

March 10, 2010 -Sea Lane Biotechnologies Demonstrates the Transformative Potential of Surrobodies™

MENLO PARK, CA, March 10, 2010 – Sea Lane Biotechnologies, LLC (Sea Lane) today announced the creation of Surrobodies™ with designed functions including bi-specific targeted binding and fusions to fully active cytokines.

July 24, 2008 - SEA LANE Unveils Potential New Class of Biotherapeutics

Menlo Park, CA - Sea Lane Biotechnologies announced the first demonstration of a new class of biotherapeutic molecules called Surrobodies™ with the potential to impart transformative new abilities and benefits into next generation biologic treatments.

April 10, 2008 - SEA LANE Scientists Create First Successful Libraries of Avian Flu Virus Antibodies

Menlo Park, CA - An international group of American and Turkish research scientists, led by Sea Lane Biotechnologies, has created the first comprehensive monoclonal antibody libraries against avian influenza (H5N1) using samples from survivors of the 2005/2006 "bird flu" outbreak in Turkey.